Anokion Is An Immune Tolerance Company Based In Ecublensswitzerlandfocused On Developing Treatments For Autoimmune Diseasesfounded In 2010Anokion Aims To Utilize The Body S Natural Tolerance Pathways To Create Targeted Therapies That Minimize The Broad Immunosuppression Seen In Traditional Treatmentsthe Company Has Developed A Proprietary Immune Tolerance Platform That Engineers Proteins To Deliver Precise Disease Therapiesits Lead Candidatekan 101Is Designed For Treating Celiac Disease And Has Shown Positive Results In Phase 2 Trialsanokion Is Also Exploring Other Candidatesincluding Ank 780 For Multiple Sclerosis And Ank 700 For Relapsing Remitting Multiple Sclerosissupported By Data From Clinical Studies Anokion Has Partnered With Major Pharmaceutical Companies Like Astellas Pharma And Celgene Corp And Has Received Significant Investment From Firms Such As Versant Ventures And Novartis Venture Fundthe Company Has Raised Over $160 Million In Funding And Holds Several Patents In The Field Of Immunology
